ERBB3 and gastric cancer: Studies have indicated that in gastric cancer with AKT inhibition, a negative feedback loop can drive the restoration of HER3 signaling, thereby mediating trastuzumab resistance (Gijsen et al., 2010; Narayan et al., 2009).